Baidu
map

盘点:2018年度新指南汇总(二)

2018-08-16 shaosai MedSci原创

2018年度新指南汇总(二)

NCCN临床实践指南:急性髓性白血病(2018.V1)

指南名称:NCCN临床实践指南:急性髓性白血病(2018.V1)

英文标题:NCCN Clinical Practice Guidelines in Oncology:Acute Myeloid Leukemia(Version 1.2018)

发布机构:美国国家综合癌症网络(NCCN,National Comprehensive Cancer Network)

发布日期:2018-2-7

简要介绍:

2018年2月,美国国家综合癌症网络(NCCN)发布了急性髓性白血病指南2018年第1版,指南主要内容包括:

指南更新摘要

急性白血病和诊断研究评估(AML-1)

APL,诱导治疗(AML-2)

APL,诱导治疗和巩固治疗(AML-3)

APL,巩固后治疗(AML-6)

APL,复发治疗(AML-7)

AML,标准剂量阿糖胞苷诱导缓解后治疗(年龄<60y)(AML-8)

AML,大剂量阿糖胞苷诱导缓解后治疗(年龄<60y)(AML-9)

AML,缓解后治疗(年龄<60y)(AML-10)

AML,诱导治疗(年龄>60y)(AML-11)

AML,标准剂量阿糖胞苷诱导后治疗(年龄≥60y)(AML-12)

AML,缓解后治疗(年龄≥60y) (AML-13)

AML,监测(AML-14)

AML,复发/难治性疾病的治疗(AML-14)

基于验证细胞遗传学和分子异常风险状态(AML-A)

CNS淋巴瘤的评估和治疗(AML-B)

支持性治疗(AML-C)

急性髓系白血病反应标准(AML-D)

治疗期间监测(AML-E)

复发/难治性疾病的治疗(AML-F)


NCCN临床实践指南:急性髓性白血病(2018.V2)

指南名称:NCCN临床实践指南:急性髓性白血病(2018.V2)

英文标题:NCCN Clinical Practice Guidelines in Oncology:Acute Myeloid Leukemia(Version 2.2018)

发布机构:美国国家综合癌症网络(NCCN,National Comprehensive Cancer Network)

发布日期:2018-8-1

简要介绍:2018年8月,美国国家综合癌症网络(NCCN)发布了急性髓性白血病指南2018年第2版,指南主要内容包括:

指南更新摘要

急性白血病和诊断研究评估(AML-1)

APL,诱导治疗(AML-2)

APL,诱导治疗和巩固治疗(AML-3)

APL,巩固后治疗(AML-6)

APL,复发治疗(AML-7)

AML,标准剂量阿糖胞苷诱导缓解后治疗(年龄<60y)(AML-8)

AML,大剂量阿糖胞苷诱导缓解后治疗(年龄<60y)(AML-9)

AML,缓解后治疗(年龄<60y)(AML-10)

AML,诱导治疗(年龄>60y)(AML-11)

AML,标准剂量阿糖胞苷诱导后治疗(年龄≥60y)(AML-12)

AML,缓解后治疗(年龄≥60y) (AML-13)

AML,监测(AML-14)

AML,复发/难治性疾病的治疗(AML-14)

基于验证细胞遗传学和分子异常风险状态(AML-A)

CNS淋巴瘤的评估和治疗(AML-B)

支持性治疗(AML-C)

急性髓系白血病反应标准(AML-D)

治疗期间监测(AML-E)

复发/难治性疾病的治疗(AML-F)


NCCN临床实践指南:急性髓性白血病(2017.V3)

指南名称:NCCN临床实践指南:急性髓性白血病(2017.V3)

英文标题:NCCN Clinical Practice Guidelines in Oncology:Acute Myeloid Leukemia(Version 3.2017)

发布机构:美国国家综合癌症网络(NCCN,National Comprehensive Cancer Network)

发布日期:2017-6-6

简要介绍:

2017年6月,美国国家综合癌症网络(NCCN)发布了急性髓性白血病指南2017年第3版,指南主要内容包括: 指南更新摘要 急性白血病和诊断研究评估(AML-1) APL,诱导治疗(AML-2) APL,巩固后治疗(AML-5) APL,复发治疗(AML-7) AML,治疗反应(年龄<60y)(AML-7) AML,标准剂量阿糖胞苷诱导缓解后治疗(年龄<60y)(AML-8) AML,大剂量阿糖胞苷诱导缓解后治疗(年龄<60y)(AML-9) AML,缓解后治疗(年龄<60y)(AML-10) AML,诱导治疗(年龄>60y)(AML-11) AML,标准剂量阿糖胞苷诱导后治疗(年龄≥60y)(AML-12) AML,缓解后治疗(年龄≥60y) (AML-13) AML,监测(AML-14) AML,复发/难治性疾病的治疗(AML-14) 基于验证细胞遗传学和分子异常风险状态(AML-A) CNS淋巴瘤的评估和治疗(AML-B) 支持性治疗(AML-C) 急性髓系白血病反应标准(AML-D) 治疗期间监测(AML-E) 复发/难治性疾病的治疗(AML-F)


NCCN临床实践指南:慢性髓性白血病(2019.V1-4)

指南名称:NCCN临床实践指南:慢性髓性白血病(2019.V1)

英文标题:NCCN Clinical Practice Guidelines in Oncology:Chronic Myeloid Leukemia (Version 1.2019)

发布机构:美国国家综合癌症网络(NCCN,National Comprehensive Cancer Network)

发布日期:2018-8-1

简要介绍:2018年8月,美国国家综合癌症网络(NCCN)发布了慢性髓性白血病指南2019年第1版,指南主要内容涉及:

更新摘要

检查

慢性期CML:初始治疗治疗

治疗响应时间表,临床注意事项以及治疗方案

进展期CML:初始治疗

基于BCR-ABL1基因突变的治疗方案

造血干细胞移植

风险评估表

加速阶段定义

爆发阶段定义

TKI治疗反映监测反映和突变分析

IBD%E8%AF%8A%E6%B2%BB%E8%BF%87%E7%A8%8B%E4%B8%AD%E7%9A%84%E8%AF%84%E4%BC%B0-Part%202" target="_blank">血液,遗传学和分析反映和复发的标准

TKI治疗停药标准

各种治疗药物毒性的管理


中医儿科临床诊疗指南·小儿口疮(修订)

指南名称:中医儿科临床诊疗指南·小儿口疮(修订)

发布机构:中医相关专家组(统称)

发布日期:2018-7-30

简要介绍:

完成文献检索、文献评价及文献总结,2 轮专家问卷调查,专家论证会,专家质量方法学评价和临床一致性评价,形成《中医儿科临床诊疗指南·小儿口疮》修订稿,提出小儿口疮诊疗指南的范围、术语和定义、诊断、辨证、治疗、预防和调护,供中医儿科行业使用。


2018 ESMO临床实践指南:成人癌痛的管理

指南名称:2018 ESMO临床实践指南:成人癌痛的管理

英文标题:Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines

发布机构:欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology)

发布日期:2018-7-23

简要介绍:

2018年,欧洲肿瘤内科学会(ESMO)发布了成人癌痛的管理指南,用以替代2012年版指南。癌症患者疼痛常见,尤其是在晚期癌症的患者当中。本文主要内容涉及成人癌痛的评估,疼痛治疗原则,以及各种类型疼痛的管理。


2018 ESMO临床实践指南:癌症患者贫血和铁缺乏的管理

指南名称:2018 ESMO临床实践指南:癌症患者贫血和铁缺乏的管理

英文标题:Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

发布机构:欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology)

发布日期:2018-2-20

简要介绍:

2018年2月,欧洲肿瘤内科学会(ESMO)发布了癌症患者贫血和铁缺乏的管理指南。贫血和缺铁是实体肿瘤和IBD%E8%AF%8A%E6%B2%BB%E8%BF%87%E7%A8%8B%E4%B8%AD%E7%9A%84%E8%AF%84%E4%BC%B0-Part%202" target="_blank">血液恶性肿瘤,尤其是接受化疗药物治疗患者最常见的并发症,本文主要针对贫血的评估以及补铁治疗方法提出指导建议,主要目的是优化癌症患者贫血和铁缺乏的管理。


重视癌症患者贫血,早期筛查与治疗铁缺乏——欧洲《成年癌症患者铁缺乏的管理意见书》解读

指南名称:重视癌症患者贫血,早期筛查与治疗铁缺乏——欧洲《成年癌症患者铁缺乏的管理意见书》解读

发布日期:2018-1-30

简要介绍:

贫血是肿瘤患者常见的并发症,而铁缺乏是其最常见的病因之一。本文对欧洲肿瘤及血液学专家组2017 年发布的《成年癌症患者铁缺乏的管理意见书》进行了解读,并与国内外肿瘤相关贫血指南、既往文献进行对比与总结,重点强调:应在癌症患者中早期定期评估和监测铁参数,早期识别和治疗贫血,以促红细胞生成类药物和铁剂补充作为绝对性铁缺乏和功能性缺铁的治疗基石,减少不必要的输血。

http://m.capotfarm.com/guideline/show_article.do?id=163361c0015a9824

NCCN临床实践指南:癌症和化疗诱导的贫血

指南名称:NCCN临床实践指南:癌症和化疗诱导的贫血(2018.V1)

英文标题:NCCN clinical practice guidelines in Oncology:Cancer- and Chemotherapy-Induced Anemia(2018.V1)

发布机构:美国国家综合癌症网络(NCCN,National Comprehensive Cancer Network)

发布日期:2017-6-23

简要介绍:2017年6月,美国国家综合癌症网络(NCCN)发布了癌症和化疗诱导的贫血指南2018年第1版,指南主要内容涉及:

指南更新摘要

贫血评估

急诊首次输血适应症和风险评估

ESA使用与红细胞输注的风险和目标

ESA应用特殊类别考虑

缺铁评估

红细胞输注的适应症

红细胞生成治疗

肠外铁剂

拒绝输血的癌症和化疗诱导的贫血患者的管理


2018 ESE临床实践指南:成人肾上腺皮质癌的管理

指南名称:2018 ESE临床实践指南:成人肾上腺皮质癌的管理

英文标题:European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors.

发布机构:欧洲内分泌学会(ESE,European Society of Endocrinology)

发布日期:2018-7-24

简要介绍:

2018年7月,欧洲内分泌学会(ESE)发布了成人肾上腺皮质癌的管理指南,肾上腺皮质癌(ACC) 是一罕见的恶性肿瘤,本文的主要目的是为临床医生提供关于肾上腺皮质癌管理的实践指导建议。内容涉及ACC的诊断和疑似ACC,疑似局部ACC的手术治疗,病例检查,分期和预后因素,影像学检查和评估,辅助治疗,复发/晚期疾病恶管理,特殊情况的管理等。


NCCN临床实践指南:神经内分泌肿瘤和肾上腺瘤

指南名称:NCCN临床实践指南:神经内分泌肿瘤和肾上腺瘤(2018.V1)

英文标题:NCCN Clinical Practice Guidelines in Oncology:Neuroendocrine and Adrenal Tumors( Version 1.2018 )

发布机构:美国国家综合癌症网络(NCCN,National Comprehensive Cancer Network)

发布日期:2018-3-29

简要介绍:

2018年3月,美国国家综合癌症网络(NCCN)发布了神经内分泌肿瘤和肾上腺瘤2018年第1版,该指南是对2017年第3版神经内分泌肿瘤的更新,指南名称由原来的神经内分泌肿瘤变为神经内分泌肿瘤和肾上腺瘤。


2018 循证共识指南:亨廷顿病神经精神症状的临床管理

指南名称:2018 循证共识指南:亨廷顿病神经精神症状的临床管理

英文标题:Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders.

发布机构:国外神经内科相关专家小组(统称)

发布日期:2018-7-19

简要介绍:

临床实践中,亨廷顿病的神经精神症状有几种治疗策略和药物是可用的,本文主要针对亨廷顿病神经精神症状包括躁动,焦虑,冷漠,精神障碍和睡眠障碍的管理提出指导建议。


2018 比利时指南:HIV感染患者潜伏性结核筛查

指南名称:2018 比利时指南:HIV感染患者潜伏性结核筛查

英文标题:2018 Belgian guidelines for the screening for latent tuberculosis in HIV-infected patients.

发布机构:国外感染病相关专家组(统称)

发布日期:2018-7-23

简要介绍:

结核杆菌是结核病的主要致病原因,本文主要回顾了HIV感染成人筛查潜伏性结核感染的最新知识,并提供了实践指导。主要建议内容涉及筛选人群,检测方法,筛查时机以及潜伏性结核感染的治疗。


肺结核影像学及分级诊断专家共识

指南名称:肺结核影像学及分级诊断专家共识

发布机构:中华医学会放射学分会(CSR,chinese society of radiology)

发布日期:2018-5-30

简要介绍:

为解决我国结核病防治工作重点和难点问题,国务院办公厅和国家卫生计生委办公厅分别下发了关于推进分级诊疗制度建设的指导意见和关于开展结核病分级诊疗和综合防治服务模式试点工作的通知等文件。作为结核病诊断的重要组成部分,影像学诊断在结核病分级诊断中的地位和作用不言而喻。为规范肺结核的影像学诊断,提高相关医务人员肺结核的临床影像诊断与鉴别诊断水平,推动全国肺结核分级诊断工作有序进行,特组织有关专家,制定本共识,希望为肺结核分级诊断做出贡献。


2018 CHEST指南:间质性肺病相关性咳嗽的治疗

指南名称:2018 CHEST指南:间质性肺病相关性咳嗽的治疗

英文标题:Treatment of Interstitial Lung Disease associated cough: CHEST guideline and expert panel report.

发布机构:美国胸科医师学会(ACCP,American College of Chest Physicians)

发布日期:2018-7-20

简要介绍:

间质性肺部引起的慢性咳嗽严重影像患者的生活质量,需要有效的治疗手段,本文主要针对咳嗽的管理和治疗提供指南建议。


2018 EAU指南:肾移植(更新版)

指南名称:2018 EAU指南:肾移植(更新版)

英文标题:European Association of Urology Guidelines on Renal Transplantation: Update 2018.

发布机构:欧洲泌尿外科学会(EAU,European Association of Urology)

发布日期:2018-7-19

简要介绍:

2018年7月,欧洲泌尿外科学会(EAU)更新发布了肾移植指南,用以替代先前版本,指南主要目的是为泌尿外科和肾脏移植外科医生提供肾移植的临床实践指导,主要聚焦药物和手术管理。


2018 BTS/RA指南:活体供肾移植

指南名称:2018 BTS/RA指南:活体供肾移植

英文标题:British Transplantation Society / Renal Association UK Guidelines for Living Donor Kidney Transplantation 2018

发布机构:英国器官移植学会(BTS,British Transplantation Society)

发布日期:2018-3-10

简要介绍:

2018年3月,英国器官移植学会(BTS)联合英国肾脏病协会(RA)共同发布了活体供肾移植指南。该指南是对2011年版指南的更新,活体供肾移植是终末期肾病患者的一种治疗选择,该指南仅涉及活体供肾移植,主要建议内容包括:移植人口统计学特征,风险评估,活体供肾管理方案以及长期结局等。


胰腺癌综合诊治指南(2018版)外科相关部分解读

指南名称:胰腺癌综合诊治指南(2018版)外科相关部分解读

发布日期:2018-6-30

简要介绍:

胰腺癌的诊治现状不容乐观,临床治疗模式亟需结合肿瘤学的新理念,在多学科协作、个体化诊疗以及多中心跨区域的临床试验中不断进行修正。笔者结合最新的中国抗癌协会胰腺癌专业委员会发布的胰腺癌综合诊治指南(2018 版)(下文简称新版指南),就胰腺癌外科综合治疗的热点问题加以解读。


2018 AASM临床实践指南:应用睡眠活动记录仪评估睡眠障碍和昼夜节律-睡眠-觉醒障碍

指南名称:2018 AASM临床实践指南:应用睡眠活动记录仪评估睡眠障碍和昼夜节律-睡眠-觉醒障碍

英文标题:Use of Actigraphy for the Evaluation of Sleep Disorders and Circadian Rhythm Sleep-Wake Disorders: An American Academy of Sleep Medicine Clinical Practice Guideline

发布机构:美国睡眠医学会(AASM,American Academy of Sleep Medicine)

发布日期:2018-7-10

简要介绍:

2018年7月,美国睡眠医学会(AASM)发布了:应用睡眠活动记录仪评估睡眠障碍和昼夜节律-睡眠-觉醒障碍指南,文章主要目的是确立成人和儿童疑似或确诊睡眠障碍和昼夜节律-睡眠-觉醒障碍患者应用睡眠活动记录仪的临床实践建议。


2018 SASM指南:成人阻塞性睡眠呼吸暂停患者的术中管理

指南名称:2018 SASM指南:成人阻塞性睡眠呼吸暂停患者的术中管理

英文标题:Society of Anesthesia and Sleep Medicine Guideline on Intraoperative Management of Adult Patients With Obstructive Sleep Apnea.

发布机构:麻醉与睡眠医学会(SASM,Society of Anesthesia and Sleep Medicine)

发布日期:2018-6-25

简要介绍:

2018年6月,麻醉与睡眠医学会(SASM)发布了成人阻塞性睡眠呼吸暂停患者的术中管理指南,主要目的是基于当前最新证据提出指导建议,内容涉及气道管理,麻醉药物的影响,麻醉方式的选择等。


2018 AASM立场声明:医用大麻和阻塞性睡眠呼吸暂停的治疗

指南名称:2018 AASM立场声明:医用大麻和阻塞性睡眠呼吸暂停的治疗

英文标题:Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement

发布机构:美国睡眠医学会(AASM,American Academy of Sleep Medicine)

发布日期:2018-3-30

简要介绍:

2018年3月,美国睡眠医学会(AASM)发布了关于医用大麻和阻塞性睡眠呼吸暂停治疗的立场声明。成人阻塞性睡眠呼吸暂停(OSA)的诊断和有效治疗是当务之急。气道正压通气治疗仍然是治疗OSA最有效的方法。本文针对医用大麻和阻塞性睡眠呼吸暂停的治疗的相关内容提出相关立场声明,指出医用大麻和/或其合成提取物不应用于OSA的治疗。


2018 WHO指南:麻风病的诊断,治疗和预防(执行概要)

指南名称:2018 WHO指南:麻风病的诊断,治疗和预防(执行概要)

英文标题:Guidelines for the diagnosis, treatment and prevention of leprosy.

发布机构:世界卫生组织(WHO,The World Health Organization)

发布日期:2018-7-12

简要介绍:

2018年7月,世界卫生组织(WHO)发布了麻风病的诊断,治疗和预防指南,主要目的是针对麻风病的诊断,治疗和预防提出循证指导建议以指导临床。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1923366, encodeId=912b1923366ad, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Thu Aug 30 04:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348256, encodeId=49b4348256f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sun Oct 07 04:21:13 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339335, encodeId=3a3d3393358a, content=学习了,感谢感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:48:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339256, encodeId=267233925684, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 18 07:47:27 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339116, encodeId=d99533911699, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 17 08:51:38 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339105, encodeId=1e7233910592, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Aug 17 08:02:25 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339049, encodeId=80f5339049db, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 16 23:50:46 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339033, encodeId=dee53390331c, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 16 23:37:31 CST 2018, time=2018-08-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1923366, encodeId=912b1923366ad, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Thu Aug 30 04:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348256, encodeId=49b4348256f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sun Oct 07 04:21:13 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339335, encodeId=3a3d3393358a, content=学习了,感谢感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:48:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339256, encodeId=267233925684, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 18 07:47:27 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339116, encodeId=d99533911699, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 17 08:51:38 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339105, encodeId=1e7233910592, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Aug 17 08:02:25 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339049, encodeId=80f5339049db, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 16 23:50:46 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339033, encodeId=dee53390331c, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 16 23:37:31 CST 2018, time=2018-08-16, status=1, ipAttribution=)]
    2018-10-07 秀红

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1923366, encodeId=912b1923366ad, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Thu Aug 30 04:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348256, encodeId=49b4348256f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sun Oct 07 04:21:13 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339335, encodeId=3a3d3393358a, content=学习了,感谢感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:48:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339256, encodeId=267233925684, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 18 07:47:27 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339116, encodeId=d99533911699, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 17 08:51:38 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339105, encodeId=1e7233910592, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Aug 17 08:02:25 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339049, encodeId=80f5339049db, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 16 23:50:46 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339033, encodeId=dee53390331c, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 16 23:37:31 CST 2018, time=2018-08-16, status=1, ipAttribution=)]
    2018-08-18 owlhealth

    学习了,感谢感谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1923366, encodeId=912b1923366ad, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Thu Aug 30 04:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348256, encodeId=49b4348256f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sun Oct 07 04:21:13 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339335, encodeId=3a3d3393358a, content=学习了,感谢感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:48:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339256, encodeId=267233925684, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 18 07:47:27 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339116, encodeId=d99533911699, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 17 08:51:38 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339105, encodeId=1e7233910592, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Aug 17 08:02:25 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339049, encodeId=80f5339049db, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 16 23:50:46 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339033, encodeId=dee53390331c, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 16 23:37:31 CST 2018, time=2018-08-16, status=1, ipAttribution=)]
    2018-08-18 惠映实验室

    学习了,谢谢分享。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1923366, encodeId=912b1923366ad, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Thu Aug 30 04:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348256, encodeId=49b4348256f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sun Oct 07 04:21:13 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339335, encodeId=3a3d3393358a, content=学习了,感谢感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:48:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339256, encodeId=267233925684, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 18 07:47:27 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339116, encodeId=d99533911699, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 17 08:51:38 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339105, encodeId=1e7233910592, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Aug 17 08:02:25 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339049, encodeId=80f5339049db, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 16 23:50:46 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339033, encodeId=dee53390331c, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 16 23:37:31 CST 2018, time=2018-08-16, status=1, ipAttribution=)]
    2018-08-17 liumin1987

    谢谢分享,学习了。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1923366, encodeId=912b1923366ad, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Thu Aug 30 04:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348256, encodeId=49b4348256f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sun Oct 07 04:21:13 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339335, encodeId=3a3d3393358a, content=学习了,感谢感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:48:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339256, encodeId=267233925684, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 18 07:47:27 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339116, encodeId=d99533911699, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 17 08:51:38 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339105, encodeId=1e7233910592, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Aug 17 08:02:25 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339049, encodeId=80f5339049db, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 16 23:50:46 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339033, encodeId=dee53390331c, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 16 23:37:31 CST 2018, time=2018-08-16, status=1, ipAttribution=)]
    2018-08-17 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1923366, encodeId=912b1923366ad, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Thu Aug 30 04:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348256, encodeId=49b4348256f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sun Oct 07 04:21:13 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339335, encodeId=3a3d3393358a, content=学习了,感谢感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:48:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339256, encodeId=267233925684, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 18 07:47:27 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339116, encodeId=d99533911699, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 17 08:51:38 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339105, encodeId=1e7233910592, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Aug 17 08:02:25 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339049, encodeId=80f5339049db, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 16 23:50:46 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339033, encodeId=dee53390331c, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 16 23:37:31 CST 2018, time=2018-08-16, status=1, ipAttribution=)]
    2018-08-16 清风拂面

    谢谢分享学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1923366, encodeId=912b1923366ad, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Thu Aug 30 04:41:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348256, encodeId=49b4348256f4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sun Oct 07 04:21:13 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339335, encodeId=3a3d3393358a, content=学习了,感谢感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 11:48:52 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339256, encodeId=267233925684, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Aug 18 07:47:27 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339116, encodeId=d99533911699, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Aug 17 08:51:38 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339105, encodeId=1e7233910592, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Aug 17 08:02:25 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339049, encodeId=80f5339049db, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 16 23:50:46 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339033, encodeId=dee53390331c, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 16 23:37:31 CST 2018, time=2018-08-16, status=1, ipAttribution=)]
    2018-08-16 惠映实验室

    学习了,谢谢分享。

    0

相关资讯

MedPage:加拿大新指南称糖尿病患者40岁时应该使用他汀类药物

根据加拿大最新指导原则,所有糖尿病患者到40岁时应该开始服用他汀类药物,55岁时服用降血压药物,尽管他们在当时没有其它危险因素。 准则委员会主席、多伦多圣迈克尔医院的Alice Cheng博士说,该指导原则也建议那些年龄30岁以上、患糖尿病至少15年的患者也应该开始使用他汀类药物。 Cheng对MedPage Today说,“在加拿大,仅13%的2型糖尿病患者在血糖、血压和LDL胆固醇控制3个

世卫组织称抗艾治疗应更早启动

世界卫生组织6月30日发布了治疗和预防艾滋病病毒感染的新指南,提高了CD4细胞计数警戒值,并建议更早实施抗逆转录病毒治疗(抗艾治疗)。 世卫组织先前设定的CD4细胞计数警戒值为每立方毫米350个或以下。最新指南将这一数字提升到500个。这意味着对艾滋病病毒感染者开始治疗的时间将提早。而对孕妇和哺乳期女性等特定感染人群,指南建议不论其CD4细胞数是多少,均应进行抗逆转录病毒治疗

盘点:2018年度血液系统疾病相关新指南汇总(一)

【盘点】2018年度血液系统疾病相关新指南汇总(一)

Ann Intern Med:美三大学会吵架!针对"美国医师协会新指南放松控糖目标:大部分患者HbA1c<8%"

近日,美国医师协会发表新指南,推荐大部分成人2型糖尿病患者的糖化血红蛋白(HbA1c)目标值为7%~8%。

Baidu
map
Baidu
map
Baidu
map